Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas

Key points

• In this article LLY Follow your favorite stocks CREATE FREE ACCOUNT watch now Jacob Van Naarden is busy.
• In addition to running Eli Lilly 's oncology business, he's now responsible for finding the drugmaker's next opportunities as head of business development.
• And Lilly, now the world's largest pharmaceutical company, is hungrier than ever for deals.
• "The company's financial strength right now, driven mostly by the weight loss business, is so strong," Van Naarden said in an interview at the American Society of Clinical Oncology's annual meeting.
• "We have this really like almost generational opportunity to redeploy that capital in all of our disease areas to not only fuel growth for the company in the decades to come, but to help a lot more patients with all different kinds of diseases, and so we're executing against that strategy." Jacob S.